“Zasocitinib (TAK-279), a Selective, Oral TYK2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis”. SKIN The Journal of Cutaneous Medicine, vol. 8, no. 6, Nov. 2024, p. s441, https://doi.org/10.25251/skin.8.supp.441.